Detailed description page of B3Pdb


This page provides detail information of Selected ID b3pdb_0007
Primary information
B3PDB IDb3pdb_0007
Peptide NameD-T7
PEPTIDE SEQUENCE (1-letter)HRPYIAHC
PEPTIDE SEQUENCE (3-letter)HisArgProTyrIleAlaHisCys
N-terminal modificationNA
C-terminal modificationCysteine on C-terminal
Chemical modificationNA
Peptide Length7
ConformationLinear
Peptide NatureNA
Source/Origin of peptideChemically synthesized
SMILESN[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CS)C(=O)O
Cell LinebEnd.3 and c6 cells
In vitro CONCENTRATIONNA
In vitro METHODConfocal microscopy
In vitro RESULTIt crosses the BBB.
ANIMAL MODELMice
In vivo CONCENTRATIONPTX-1.7 mg/kg, CD-3.6 mg/kg
In vivo MODE OF DELIVERYIntravenous
In vivo METHODNA
In vivo RESULTNA
ACTIOND-T7 Peptide Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Ant
TRANSPORT TYPENA
SUBCELLULAR LOCALISATIONNA
COMBINATIONCombined with Cediranib and Paclitaxel.
PHYSICAL CONDITIONGlioma
RESPONSEStability/half life
RESULT3.31-fold higher than saline
LABELNA
PMID30525386